Alan Hawxby, MD
Transplant Surgery · Oklahoma City, OKNPI 1225047145
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,942 of the $2,333 with a category attached, or 83.2%. It is spread thinly across 25 manufacturers, the largest accounting for just 21.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $844 and has fallen 91.7% since, to $70 in 2025.
Across 63 payments — averaging $37.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$505
- Veloxis Pharmaceuticals, Inc.$307
- AbbVie$195
- Mallinckrodt Hospital Products Inc.$190
- Boston Scientific$128
- Gilead$128
- plus $880 from 19 others
What the payments were for
- Travel & lodging$572%
- Food & beverage$1,94283%
- Education$33414%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 6 | $505 |
| Veloxis Pharmaceuticals, Inc. | 8 | $307 |
| AbbVie | 11 | $195 |
| Mallinckrodt Hospital Products Inc. | 4 | $190 |
| Boston Scientific | 1 | $128 |
| Gilead | 8 | $128 |
| E.r. Squibb & Sons, L.L.C. | 1 | $123 |
| Sanofi-aventis U.S. LLC | 1 | $122 |
| Johnson & Johnson | 1 | $94 |
| Agiliti Surgical, Inc. | 1 | $77 |
| Intercept Pharmaceuticals, Inc. | 5 | $73 |
| Paragonix Technologies, Inc. | 1 | $68 |
| Merck | 2 | $41 |
| Baxter Healthcare | 1 | $34 |
| Pacira Pharmaceuticals Incorporated | 1 | $28 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $27 |
| Acera Surgical, Inc. | 1 | $27 |
| Innovation Technologies Inc | 1 | $26 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Calliditas Therapeutics US Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Mimedx Group, Inc. | 1 | $20 |
| KCI USA, Inc. | 1 | $20 |
| Novartis | 1 | $19 |
| AstraZeneca | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Signia$334
- Envarsus$249
- TERLIVAZ$145
- TheraSphere Y90 Glass Microspheres 10 GBq$128
- NULOJIX$123
- THYMOGLOBULIN$122
How this compares
Too few transplant surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other transplant surgery in Oklahoma City
- Yi HuangOklahoma City$16K
- Shinichiro YokotaOklahoma City$4K
- Maheswaran PitchaimuthuOklahoma City$3K
- Vivek KohliOklahoma City$3K
- John DuffyOklahoma City$1K
- Nitin AbrolOklahoma City$1K
- Anthony SebastianOklahoma City$1K
- Shi-Feng LiOklahoma City$448
- Ye YongOklahoma City$287
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.